Abstract
Prodrug strategies have played a prominent role in the development of drugs to treat viral diseases. Implementation of prodrug approaches has been shown to improve the drug characteristics of agents to treat a wide range of viral diseases, including HIV, HBV, HCV, CMV, VZV, EBV, HSV and influenza. Prodrugs of antiviral agents have been used to address issues such as poor intestinal absorption because of the lack of membrane permeability or poor solubility. Prodrugs have also been used to enable tissue targeting. This chapter addresses the issues and challenges associated with prodrug design and development and highlights a number of case studies where prodrugs of antiviral agents have been used to solve pharmacokinetic or pharmaceutics problems that limited the development of the parent drug.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
